OPTICAL PRISM | INFOCUS
Advancing the Science of Dry Eye
I-Med Pharma leads the way
BY JANET LEES
I-MED Pharma provides ocular surface disorder ( OSD ) solutions to Canadian ophthalmologists , optometrists , and the global eye care community . The company has established itself as the leader in dry eye diagnostics , management , and treatment solutions with 33 years of research and innovation behind their name .
A pioneer in the field of artificial tears and ocular hygiene cleansers , I-MED Pharma ’ s signature product lines include I-DROP ® and I-LID ’ N LASH ® , which are now sold around the world . hygiene cleansers , a night-time dry eye ointment , an IRPL ® treatment solution , punctum plugs , nutritional supplements , and therapeutic accessories .
The company dates back to 1989 , when Dr . Hofmann , PhD in biochemistry , opened a small office in Montreal under the name Dolimens Canada Inc ., a subsidiary of the Lyon , France-based , Laboratoires
WE UNDERSTAND THE PATHOLOGY AND THE DISEASE ITSELF , SO WE DO THE SCIENCE , UNDERSTAND THE SCIENCE , DEVELOP THE PRODUCTS , AND KEEP TESTING AND IMPROVING .
“ Our mission is to bring complete relief to dry eye and ocular surface disease patients worldwide ,” explains Ilan Hofmann , I-MED Pharma ’ s Founder , Chairman , and Chief Scientific Officer . “ To do this , we continually research and develop the most effective and advanced solutions for dry eye disease .”
I-MED ’ s uniquely formulated line of OSD products include state-ofthe-art diagnostic tools , preservative-free artificial tears , ocular
Domilens . It quickly grew into a fully independent , wholly owned Canadian company , which was renamed I-MED Pharma Inc . in 1994 .
In 2017 , Dr . Hofmann transitioned from President and CEO of I-MED Pharma to Chairman and Chief Scientific Officer of the company . This allowed him to focus his attention on the research and development of new products as the backbone and future of the company . Daniel Hofmann , MBA , BSc in biochem- istry , was appointed President and CEO , and remains focused on the continued growth and expansion of the company , through both product development and global distribution partnerships .
“ As a research-based firm with the vision to be the most important dry eye and ocular surface disease company in the world , I-MED Pharma provides innovative OSD solutions to the global optometry and ophthalmology community ,” says Dr . Hofmann .
I-MED Pharma continuously invests heavily in R & D to create effective , leading-edge products for the management of dry eye disease . “ We understand the pathology and the disease itself , so we do the science , understand the science , develop the products , and keep testing and improving .”
I-MED Pharma ’ s products are sold directly to eye care professionals and a network of distributors exclusively . OP
34 OPTICAL PRISM | May 2022